Vandetanib

220px
Vandetanib
Systematic (IUPAC) name
N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7- [(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine
Identifiers
CAS number	443913-73-3
ATC code	?
PubChem	3081361
Chemical data
Formula	C22H24BrFN4O2
Mol. mass	475.354 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	5 days (mean)
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

WikiDoc Resources for Vandetanib
Articles
Most recent articles on Vandetanib Most cited articles on Vandetanib Review articles on Vandetanib Articles on Vandetanib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Vandetanib Images of Vandetanib Photos of Vandetanib Podcasts & MP3s on Vandetanib Videos on Vandetanib
Evidence Based Medicine
Cochrane Collaboration on Vandetanib Bandolier on Vandetanib TRIP on Vandetanib
Clinical Trials
Ongoing Trials on Vandetanib at Clinical Trials.gov Trial results on Vandetanib Clinical Trials on Vandetanib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Vandetanib NICE Guidance on Vandetanib NHS PRODIGY Guidance FDA on Vandetanib CDC on Vandetanib
Books
Books on Vandetanib
News
Vandetanib in the news Be alerted to news on Vandetanib News trends on Vandetanib
Commentary
Blogs on Vandetanib
Definitions
Definitions of Vandetanib
Patient Resources / Community
Patient resources on Vandetanib Discussion groups on Vandetanib Patient Handouts on Vandetanib Directions to Hospitals Treating Vandetanib Risk calculators and risk factors for Vandetanib
Healthcare Provider Resources
Symptoms of Vandetanib Causes & Risk Factors for Vandetanib Diagnostic studies for Vandetanib Treatment of Vandetanib
Continuing Medical Education (CME)
CME Programs on Vandetanib
International
Vandetanib en Espanol Vandetanib en Francais
Business
Vandetanib in the Marketplace Patents on Vandetanib
Experimental / Informatics
List of terms related to Vandetanib

Overview

Vandetanib (rINN, trade name Zactima), also known as ZD6474, is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. It is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).

Vandetanib is being developed by AstraZeneca.

External links

• Cancerline.com: Vandetanib Information for Physicians
• AZ-Trials.com: AstraZeneca Clinical Trials Patient Recruiting (US)